Melanotan-II is related to, but different from, afamelanotide, an approved drug used to treat the skin condition erythropoietic protoporphyria
As highlighted earlier, the Phase 2 clinical trials demonstrated unprecedented mean body weight reductions, indicating its superior efficacy compared to existing monotherapies
Jin J, Byun JK, Choi YK, Park KG
Each dose was held for 4 weeks before escalating
Specifically, this paper delved into an overview of GLP-1s role at the physiological level as a modulator of the incretin effect, which is an important hormonal pathway whose dysregulation was explained to be implicated in the pathogenesis of T2DM